A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure.
|Type carcinoma:||NSCLC met mutatie|
|Lijn:||2de lijns na osimertinib|
- Participant must have histologically or cytologically confirmed, locally advanced or
metastatic, non-squamous NSCLC, characterized at or after the time of locally advanced
metastatic disease diagnosis by either EGFR Exon 19del or Exon 21 L858R mutation
- Participant must have progressed on or after osimertinib monotherapy as the most recent
line of treatment. Osimertinib must have been administered as either the first-line
treatment for locally advanced or metastatic disease or in the second-line setting after
prior treatment with first- or second-generation EGFR TKI.
- Participant must have at least 1 measurable lesion, according to RECIST v1.1
- A participant with definitively, locally treated brain metastases must be clinically stable
and asymptomatic, with or without low-dose corticosteroid treatment (≤10 mg prednisone
or equivalent), for at least 14 days prior to randomization.
- ECOG 0-1
Participant received prior systemic anticancer therapy in the locally advanced or metastatic setting, or in the adjuvant setting, for the same nonsquamous NSCLC intended for treatment now
Participant received radiotherapy for palliative treatment of NSCLC less than 14
days prior to randomization.
Participant has active brain metastases not definitively treated with local therapy
Participant has known small cell transformation
Participant has uncontrolled tumor-related pain.
Participant has a medical history of ILD, including drug-induced ILD or radiation
Een overzicht van alle lopende studies binnen het longkankernetwerk. Filter op type mutatie:
2de lijns | stadium IIIb-IV | AGA-positive
Stadium IV | 2de lijns
EGFR | 2de lijn | stadium IV
1ste lijn | Stadium IV
2de lijn | EGFR | stadium IIIIB - IV
Stadium IV | 2de lijn | KRAS G12C mutatie
stadium IV - 1ste, 2de of 3de lijn
2de lijn - stadium IV
2de lijns | Stadium III/IV
Stadium IIIB-IV | Eerstelijns | ROS1 mutation
Eerstelijn | Fase I
Lijst van verschillende programma's